A Phase 3 interventional study of brentuximab vedotin and doxorubicin in Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma and T-Cell Lymphoma, sponsored by Seagen Inc.. Completed at 144 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-30.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, Large-Cell, Anaplastic.
Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, this one has the largest enrollment, is one of 4 that started in 2013, is the only one in phase 3, and was the 10th registered.
397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.
Browse Lymphoma, Large-Cell, Anaplastic studies →1 of the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic is open now, in 1 country. Recruiting first, the newest first:
New York Medical College · Sites in United States
Ages 1–39
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 452 is above the median of 37 across 306 interventional studies indexed under Lymphoma, Large-Cell, Anaplastic.
Median enrollment 44 across the 21 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
15 studies in Lymphoma, Large-Cell, Anaplastic by Pfizer: none open now, 1 under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 15 studies in Lymphoma, Large-Cell, Anaplastic by Pfizer, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2013, is the only one in phase 3, and was the 11th registered.
Pfizer’s Lymphoma, Large-Cell, Anaplastic studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Lymphoma, Large-Cell, Anaplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cyclophosphamide, doxorubicin, vincristine, and prednisone
Drug: doxorubicin · Drug: prednisone · Drug: vincristine · Drug: cyclophosphamide
brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone
Drug: brentuximab vedotin · Drug: doxorubicin · Drug: prednisone · Drug: cyclophosphamide
1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
Also known as: Adcetris; SGN-35
50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Progression-free Survival Per Independent Review Facility (IRF)
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.
Time frame: Up to 60 months
Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.
Time frame: Up to 60 months
Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)
The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.
Time frame: Up to 8.34 months
Overall Survival (OS)
The time from randomization to death due to any cause.
Time frame: Up to 90 months
Objective Response Rate (ORR) Per IRF at End of Treatment
The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.
Time frame: Up to 8.34 months
Incidence of Adverse Events (AEs)
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to 8.28 months
Incidence of Laboratory Abnormalities
Number of participants who experienced a Grade 3 or higher laboratory toxicity.
Time frame: Up to 8.28 months
Jan2013-Nov2016
| Milestone | A+CHP | CHOP |
|---|---|---|
| Started | 226 | 226 |
| Completed | 131 | 116 |
| Not completed | 95 | 110 |
| Withdrew: Withdrawal by subject | 22 | 16 |
| Withdrew: Lost to follow-up | 3 | 5 |
| Withdrew: Death | 68 | 89 |
| Withdrew: Not eligible, no study drug received | 1 | 0 |
| Withdrew: Change of diagnosis | 1 | 0 |
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.
| months | A+CHP | CHOP |
|---|---|---|
| Progression-free Survival Per Independent Review Facility (IRF) | 48.20 (8.87 to NA) | 20.80 (4.70 to NA) |
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.
| months | A+CHP | CHOP |
|---|---|---|
| Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL) | 55.66 (15.61 to NA) | 32.03 (4.57 to NA) |
The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.
| Participants | A+CHP | CHOP |
|---|---|---|
| Complete Remission (CR) Rate Per IRF at End of Treatment (EOT) | 153 | 126 |
The time from randomization to death due to any cause.
| Months | A+CHP | CHOP |
|---|---|---|
| Overall Survival (OS) | NA (0.0 to 86.5) | NA (0.1 to 90.0) |
The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.
| Participants | A+CHP | CHOP |
|---|---|---|
| Objective Response Rate (ORR) Per IRF at End of Treatment | 188 | 163 |
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment.
| Participants | A+CHP | CHOP |
|---|---|---|
| Any treatment-emergent AE | 221 | 221 |
| Blinded study treatment-related AE | 201 | 193 |
| CHP treatment-related AE | 198 | 205 |
| Any serious adverse event (SAE) | 87 | 87 |
| Blinded study treatment-related SAE | 58 | 45 |
| CHP treatment-related SAE | 62 | 53 |
| Treatment discontinuations due to AE | 14 | 15 |
| Treatment discontinuations due to blinded study treatment-related AE | 10 | 10 |
| Treatment discontinuations due to CHP treatment-related AE | 8 | 7 |
Number of participants who experienced a Grade 3 or higher laboratory toxicity.
| Participants | A+CHP | CHOP |
|---|---|---|
| Any Chemistry Test | 25 | 23 |
| Alanine Aminotransferase High | 3 | 1 |
| Albumin Low | 2 | 3 |
| Alkaline Phosphatase High | 1 | 0 |
| Calcium Low | 1 | 1 |
| Glucose High | 8 | 6 |
| Phosphate Low | 4 | 3 |
| Potassium High | 0 | 2 |
| Potassium Low | 3 | 2 |
| Sodium High | 1 | 0 |
| Sodium Low | 4 | 6 |
| Urate High | 5 | 2 |
| Any Hematology Test | 68 | 78 |
| Absolute Neutrophil Count Low | 17 | 19 |
| Hemoglobin High | 1 | 0 |
| Hemoglobin Low | 9 | 13 |
| Leukocytes Low | 12 | 21 |
| Lymphocytes High | 0 | 1 |
| Lymphocytes Low | 52 | 61 |
| Neutrophils Low | 17 | 19 |
| Platelets Low | 1 | 1 |
Collected over Non-serious AEs followed up to 8 months. Serious AEs followed up to 90 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A+CHP | 67/223 (30%) | 89/223 (39.9%) | 220/223 (98.7%) |
| CHOP | 89/226 (39.4%) | 90/226 (39.8%) | 218/226 (96.5%) |
| A+CHP Subgroup | 1/3 (33.3%) | — | — |
| Event | A+CHP | CHOP | A+CHP Subgroup |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 32/223 | 26/226 | — |
| PneumoniaInfections and infestations | 11/223 | 3/226 | — |
| Anaplastic large cell lymphoma T- and null-cell typesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/223 | 11/226 | — |
| PyrexiaGeneral disorders | 9/223 | 8/226 | — |
| NeutropeniaBlood and lymphatic system disorders | 8/223 | 6/226 | — |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/223 | 6/226 | — |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/223 | 0/226 | — |
| SepsisInfections and infestations | 5/223 | 4/226 | — |
| DiarrhoeaGastrointestinal disorders | 4/223 | 3/226 | — |
| NauseaGastrointestinal disorders | 1/223 | 4/226 | — |
| Event | A+CHP | CHOP | A+CHP Subgroup |
|---|---|---|---|
| NauseaGastrointestinal disorders | 114/223 | 91/226 | — |
| Peripheral sensory neuropathyNervous system disorders | 112/223 | 108/226 | — |
| ConstipationGastrointestinal disorders | 98/223 | 94/226 | — |
| DiarrhoeaGastrointestinal disorders | 93/223 | 55/226 | — |
| NeutropeniaBlood and lymphatic system disorders | 87/223 | 81/226 | — |
| PyrexiaGeneral disorders | 86/223 | 74/226 | — |
| FatigueGeneral disorders | 83/223 | 80/226 | — |
| HypertensionVascular disorders | 71/223 | 68/226 | — |
| AnaemiaBlood and lymphatic system disorders | 64/223 | 49/226 | — |
| Night sweatsSkin and subcutaneous tissue disorders | 46/223 | 63/226 | — |
| Age, Categorical(Participants) | A+CHP | CHOP | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 157 | 156 | 313 |
| >=65 years | 69 | 70 | 139 |
| Age, Continuous(years) | A+CHP | CHOP | Total |
|---|---|---|---|
| Median | 58 (18 to 85) | 58 (18 to 83) | 58 (18 to 85) |
| Sex: Female, Male(Participants) | A+CHP | CHOP | Total |
|---|---|---|---|
| Female | 93 | 75 | 168 |
| Male | 133 | 151 | 284 |
| Ethnicity (NIH/OMB)(Participants) | A+CHP | CHOP | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 4 | 14 |
| Not Hispanic or Latino | 186 | 193 | 379 |
| Unknown or Not Reported | 30 | 29 | 59 |
| Race/Ethnicity, Customized(Participants) | A+CHP | CHOP | Total |
|---|---|---|---|
| Asian | 45 | 54 | 99 |
| Black or African American | 12 | 6 | 18 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White | 139 | 142 | 281 |
| Other | 3 | 2 | 5 |
| Unknown | 26 | 22 | 48 |
| Region of Enrollment(Participants) | A+CHP | CHOP | Total |
|---|---|---|---|
| United States | 70 | 57 | 127 |
| Japan | 20 | 23 | 43 |
| South Korea | 17 | 23 | 40 |
| Italy | 17 | 20 | 37 |
| France | 18 | 18 | 36 |
| Germany | 15 | 12 | 27 |
| Spain | 15 | 11 | 26 |
| Czechia | 10 | 12 | 22 |
| United Kingdom | 7 | 14 | 21 |
| Australia | 6 | 8 | 14 |
| Denmark | 9 | 5 | 14 |
| Israel | 8 | 4 | 12 |
| Hungary | 4 | 5 | 9 |
| Taiwan, Province Of China | 5 | 4 | 9 |
| Poland | 2 | 5 | 7 |
| Canada | 3 | 3 | 6 |
| Romania | 0 | 2 | 2 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | A+CHP | CHOP | Total |
|---|---|---|---|
| Grade 0 | 85 | 93 | 178 |
| Grade 1 | 90 | 86 | 176 |
| Grade 2 | 51 | 47 | 98 |
Showing the first 100 of 144 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2013 to primary completion in Aug 2018, 66 months.
Results were first posted in Jul 2019, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lymphoma, Large-Cell, Anaplastic →